On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.

The study showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks.

Efficacy was observed throughout the 24 hours, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.

Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care. Baxdrostat was generally well-tolerated, with a safety ...